Bender Robert & Associates Grows Position in Eli Lilly and Company (NYSE:LLY)

Bender Robert & Associates raised its holdings in Eli Lilly and Company (NYSE:LLY) by 0.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 19,813 shares of the company’s stock after acquiring an additional 22 shares during the period. Eli Lilly and Company makes up 2.9% of Bender Robert & Associates’ investment portfolio, making the stock its 12th largest position. Bender Robert & Associates’ holdings in Eli Lilly and Company were worth $11,549,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Fairfield Bush & CO. bought a new position in Eli Lilly and Company in the 1st quarter worth about $107,000. Roundview Capital LLC boosted its position in shares of Eli Lilly and Company by 2.6% in the first quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock valued at $589,000 after acquiring an additional 53 shares during the period. Merit Financial Group LLC purchased a new position in Eli Lilly and Company during the first quarter valued at approximately $210,000. NewEdge Advisors LLC increased its holdings in Eli Lilly and Company by 9.9% during the 1st quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock worth $15,193,000 after acquiring an additional 4,774 shares during the period. Finally, Barometer Capital Management Inc. bought a new stake in Eli Lilly and Company during the 1st quarter worth approximately $561,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.6 %

NYSE:LLY traded down $4.82 during trading hours on Thursday, reaching $745.95. The company’s stock had a trading volume of 1,701,414 shares, compared to its average volume of 3,067,519. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The firm has a market capitalization of $708.77 billion, a price-to-earnings ratio of 129.32, a PEG ratio of 1.63 and a beta of 0.34. The firm has a 50-day simple moving average of $764.03 and a 200-day simple moving average of $657.67. Eli Lilly and Company has a 1 year low of $367.35 and a 1 year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same period last year, the firm earned $2.09 earnings per share. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. Research analysts expect that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the sale, the insider now owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of recent analyst reports. Barclays boosted their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Cantor Fitzgerald restated an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research note on Monday. Wells Fargo & Company raised their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Finally, TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.